TARS-Activity Compounds Enhancing Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of angiogenesis pathways is limited, hindering effective treatments for conditions characterized by insufficient angiogenesis, and the role of threonyl-tRNA synthetase (TARS) in promoting angiogenesis has not been fully explored.
Innovation Solution
Methods and compounds are developed to enhance TARS activity in cells, including administering TARS-activity-enhancing compounds like TNF-α or threonyl-tRNA synthetase molecules to increase angiogenesis, which can be used to treat conditions such as cancer and immune system disorders by promoting endothelial cell migration and tube formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TARS activity is enhanced to promote angiogenesis, then treatment outcomes for conditions like cancer and immune system disorders improve, but the complexity of understanding and controlling the angiogenesis pathways increases
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to enhance TARS activity. These compounds serve as mediators between the administered substance and the TARS enzyme, selectively modulating TARS function to promote angiogenesis without requiring complete understanding or control of all angiogenesis pathway components.
Solution Approach 2:
The patent employs compounds that alter the functional parameters of TARS enzyme activity. By changing the catalytic efficiency or substrate affinity of TARS through small molecule interaction, the system achieves enhanced angiogenesis promotion through a controllable parameter modification rather than complex pathway manipulation.
2Productivity
If TARS-activity-enhancing compounds are administered to increase angiogenesis, then endothelial cell migration and tube formation are improved, but the precision of controlling angiogenesis specifically without affecting other cellular processes decreases
Solution Approach 1:
The patent utilizes feedback mechanisms where the enhancement of TARS activity creates a self-regulating system. The increased TARS activity leads to elevated protein synthesis rates that specifically support angiogenesis, and the biological system's natural feedback loops help maintain specificity by responding to the actual physiological needs of the tissue.
Solution Approach 2:
The TARS enzyme and the cellular machinery it supports perform the angiogenesis function autonomously once activated by the enhancing compound. The compound initiates the process, but the subsequent endothelial cell migration and tube formation are self-driven biological processes that do not require continuous external control, thereby maintaining specificity through natural cellular regulation.
Data Source
AI summary
The invention includes, in part, methods and compounds for treating diseases and conditions characterized by reduced threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is reduced as compared to normal. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess a treatment for a disease or condition characterized by reduced TARS activity.